| International Stem Cell (OTCBB:ISCO), www.internationalstemcell.com, announced today that Dr. Alan Copperman, M.D. has joined the company's Scientific Advisory Board. International Stem Cell Corporation, "ISCO" is a California company that has developed, for the first time under controlled conditions, human stem cell lines that promise to eliminate the rejection of transplanted cells by the patient's immune system. ISCO's technology, called parthenogenesis, results in the creation of pluripotent human stem cell lines (called phESC) from unfertilized human eggs. This new methodology offers the potential to create the first "Stem Cell Bank" with the capacity to provide rejection-resistant stem cells that can become any cell in the human body, and also addresses critical ethical issues by eliminating the need to use fertilized embryos. ISCO also produces and sells the Lifeline brand of specialized cells and growth media worldwide for therapeutic research. Dr. Copperman is Director of the Division of Reproductive Endocrinology as well as Vice-Chairman of the Department of Obstetrics, Gynecology, and Reproductive Science at Mount Sinai Medical Center in New York. Additionally, he heads the Reproductive Medicine Associates of New York, LLP (RMA of New York); a leading full-service Manhattan-based fertility center. RMA of New York's success in the fertility-preserving technology of oocyte freezing and thawing has garnered attention worldwide. An experienced and respected clinician, he has published numerous award-winning papers and textbook chapters on egg freezing, infertility, polycystic ovarian syndrome, and pelvic surgery. New York Magazine has recognized Dr. Copperman as one of its Best Doctors five years in a row from 2002 to 2006, and the American Fertility Association awarded him its 2003 Family Building Award. Dr. Copperman received his undergraduate degree from the University of Pennsylvania and his medical degree from New York Medical College. After earning his degree in medicine, Dr. Copperman completed residency in Ob/Gyn at Yale-New Haven Hospital, then continued his training at Mount Sinai Medical Center in New York as the Martin J. Clyman Fellow in Reproductive Endocrinology. Dr. Copperman is board certified in both Ob/Gyn and reproductive endocrinology. He is a Fellow of the American College of Obstetricians and Gynecologists and of the American Society for Reproductive Medicine. "Dr. Copperman's research and accomplishments in the field of Reproductive Endocrinology and, in particular, the freezing and handling of human eggs, are of particular importance to International Stem Cell," said Jeff Krstich, CEO. "Innovations that increase the efficiencies in the stem cell creation process are beneficial and serve to accelerate progress. We are fortunate to add such a noted and respected researcher and clinician to our prestigious Scientific Advisory Board." In addition to Dr. Copperman, ISCO's Scientific Advisory Board includes: Hans S. Keirstead, PhD- Dr. Keirstead is the Principal Independent Scientific Advisor and one of the leading lights in the development of Stem Cell therapy. He is currently working with ISCO's parthenote stem cells to create transplant therapies for the possible treatment of macular degeneration and retinitis pigmentosa (announced March 19, 2007). A Canadian-born neuroscientist, he received his Ph.D. from the University of British Columbia in Vancouver, Canada. His Ph.D. thesis concerned his invention of a novel method for regenerating damaged spinal cords, and formed the basis of several worldwide patents. His Ph.D. work constituted the first demonstration of functional regeneration of the injured adult spinal cord, and for his achievements he received the Cameron Award for the outstanding Ph.D. thesis in Canada. In 2000, Dr. Keirstead became a tenure-track Assistant Professor in the Reeve-Irvine Research Center at the University of California Irvine. The Reeve-Irvine Research Center, founded by actor Christopher Reeve and philanthropist Joan Irvine, is a leading center for spinal cord injury research. There, he directs a 20 person research team investigating the cellular biology and treatment of spinal cord trauma; research that also has significance for multiple sclerosis and other diseases of the nervous system. Bernard M. Wagner, MD- Dr. Wagner is an Emeritus Research Professor of Pathology at New York University Medical Center and Emeritus Clinical Professor of Pathology, College of Physicians & Surgeons, Columbia University, New York. He is a Diplomat of the American Board of Pathology and Diplomat (Hon.), of the American College of Veterinary Pathologists. Dr. Wagner is also a Fellow of the Royal College of Pathologists (London); Fellow, Academy of Toxicologic Sciences; Fellow, New York Academy of Medicine; Member, Committee on Toxicology, National Academy of Sciences; Qualified Expert, European Council, Safety Assessment; Member Executive Committee, Board of Directors, American Registry of Pathology, Armed Forces Institute of Pathology; Member, GRAS Expert Panel (FDA); and Fellow of American Academy of Arts and Sciences. Currently, he is a Senior Consultant for Roche and Consultant for ICOS Corp. Michael Karas, PhD, MD- Dr. Karas was educated in Russia and Israel and came to the United States to join the Diabetes Branch of the National Institute of Diabetes and Digestive and Kidney Diseases. He led the Cell Engineering Group of Cambrex Corporation and currently leads a program at FMC Corporation developing novel platform technologies for the delivery of active ingredients. He is a specialist in cellular and molecular biology as they relate to cell differentiation. ABOUT INTERNATIONAL STEM CELL CORPORATION: International Stem Cell is a biotechnology company currently focused on developing therapeutic and research products. In the area of therapeutic product development, ISCO's objective is to create an unlimited source of human cells for use in the treatment of several diseases, including diabetes, liver disease and retinal disease through cell transplant therapy. In furtherance of this objective, ISCO has developed pluripotent human stem cells from unfertilized human eggs, and techniques to cause those stem cells to be "differentiated" into the specific cell types required for transplant. It has developed manufacturing protocols to produce the cells minimizing contamination with animal by-products, a characteristic likely to be important in meeting U.S. Food and Drug Administration requirements. ISCO also provides the specialized cells and growth media needed for therapeutic cell transplantation research to academic and commercial researchers in related fields. For more information, visit the ISCO website at: www.internationalstemcell.com. To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 Forward-Looking Statements Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will,""believes,""plans,""anticipates,""expects,""estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements. |
